September 24, 2021
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, KNOW AML spoke to Amir Fathi, Massachusetts General Hospital, Boston, US. We Asked, How could new immunotherapy treatments in acute myeloid leukemia (AML) change current practice? Fathi begins by discussing immunotherapeutic gemtuzumab and its practical application. He goes on to outline emerging drugs and the molecular targets for these immunotherapies such as flotetuzumab, for patients with relapsed/refractory or early stage AML. Finally, Fathi discusses interesting molecular targets such as CD47, p53 and CD70 and their potential treatment routes.